Melbourne’s Peter MacCallum Cancer Centre is joining forces with America’s Penn Medicine (University of Pennsylvania Health System), aiming to establish laboratory-clinical-research initiatives and open more clinical trials for Australian and American cancer patients.
Chronic lymphocytic leukaemia (CLL) patients who are refractory or resistant to treatment can be encouraged by data showing significantly longer survival without disease progression with a treatment combining venetoclax and rituximab compared to treatment with bendamustine plus rituximab.
An AI-powered, virtual platform is being developed to improve care for patients living with genetic disorders, as part of a Digital Health CRC project led by Peter MacCallum Cancer Centre and Swinburne University of Technology.
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.